BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Quetzal Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Quetzal Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07504458-3093@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Arsenic trioxide (QTX-2101): Phase 3 readout est. (NCT07504458)
DESCRIPTION:Arsenic trioxide (QTX-2101)\, phase 3\, Acute Myeloid Leukemia.
 \nStudy: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Pa
 tients With Acute Promyelocytic Leukemia\nEstimated primary completion: Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/arsenic-tri
 oxide-qtx-2101#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07504458
URL:https://assetmemo.bio/drug/arsenic-trioxide-qtx-2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
